Rapid detection of organophosphorous (OP) compounds such as paraoxon would allow taking immediate decision on efficient decontamination procedures and could prevent further damage and potential casualties. In the present study, a biosensor based on nanomagnet-silica core-shell conjugated to organophosphorous hydrolase (OPH) enzyme was designed for detection of paraoxon. Coumarin1, a competitive inhibitor of the OPH enzyme, was used as a fluorescence-generating molecule. Upon excitation of cumarin1 located at the active site of the enzyme, i.e., OPH, the emitted radiations were intensified due to the mirroring effect of the nanomagnet-silica core-shell conjugated to the enzyme. In presence of paraoxon and consequent competition with the fluorophore in occupying enzyme's active site, a significant reduction in emitted radiations was observed. This reduction was proportional to paraoxon concentration in the sample. The method worked in the 10- to 250-nM concentration range had a low standard deviation (with a coefficient of variation (CV) of 6-10%), and the detection limit was as low as 5 × 10(-6) μM.

Early diagnosis and treatment of diseases are crucial research areas of human health. For early diagnosis, one method that has proven efficient is the detection of biomarkers which can provide real‐time and accurate biological information. Most biomarker detection is currently carried out at localised dedicated laboratories using large and automated analysers, increasing waiting time and costs. Smaller, faster, and cheaper devices could potentially replace these time‐consuming laboratory analyses and make analytical results available as point‐of‐care diagnostics. Innovative biosensor‐based strategies could allow biomarkers to be tested reliably in a decentralised setting. Early diagnosis of COVID‐19 patients has a key role in order to use quarantine and treatment strategies in a timely manner. Raised levels of several biomarkers in COVID‐19 patients are associated with respiratory infections or dysfunction of various organs. Through clinical studies of COVID‐19 patient biomarkers such as ferritin, Interleukins, albumin and …are found to reveals significant differences in their excretion ranges from healthy patients and patients with SARS‐CoV‐2, in addition to the development of biomarkers based biosensor such as stated biomarkers can be used and to investigate more specific biomarkers further proteomic analysis can be performed. This review presents several biomarker alterations in COVID‐19 patients such as salivary, circulatory, coagulation, cardiovascular, renal, liver, C‐reactive protein (CRP), immunological and inflammatory biomarkers. Also, biomarker sensors based on electrochemical, optical, and lateral flow characteristics which have potential applications for SARS‐COV‐2 in the recent COVID‐19 pandemic, will be discussed.

The cover image is based on the Review Biomarker based biosensors: An opportunity for diagnosis of COVID‐19 by Reza Khaksarinejad et al., https://doi.org/10.1002/rmv.2356.

No abstract